India's Richest People 2026 edition · 1 director · Source: Hurun India
- #1,482 Ashok Kumar Windlass & family ₹1,400 Cr
Market Cap
₹1,821 Cr
WINDLAS · NSE
Share Price
₹879.70
-0.32% today
Revenue
₹904 Cr
FY 2025-26 · +19.0% YoY
EBITDA
₹105 Cr
Margin 11.6%
Net Profit
₹66.46 Cr
FY 2025-26 · +9.0% YoY
P/E (TTM)
27.1x
P/B 3.1x
ROE
12.2%
ROCE 15.8%
Debt / Equity
0.06
Interest cover 6.5x
About Windlas Biotech Limited
Data last updated:
Windlas Biotech Limited is a public limited company based in Dehradun, Uttarakhand, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 19 February 2001 and has been in existence for over 25 years.
Its director Ashok Kumar Windlass and family are #1,482 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Uttarakhand, under CIN L74899UR2001PLC033407. Its GSTIN is 05AAACW3417C1ZV (Uttarakhand). The company holds 12 GST registrations, of which 7 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 543329 and NSE: WINDLAS.
The company has an authorised share capital of ₹77.5 Cr and a paid-up capital of ₹10.55 Cr. It was formerly known as Windlas Biotech Private Limited. It is led by directors including Hitesh Windlass (Managing Director) and Manoj Kumar Windlass (Managing Director).
Its last annual general meeting (AGM) was held on 28 July 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 40/1 Mohabewala Industrial Area, Dehradun, Uttarakhand, India – 248110.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹904.09 Cr, a growth of 19% compared to the previous year. For the same year it recorded a net profit of ₹66.46 Cr (net margin 7.4%) and EBITDA of ₹104.75 Cr (EBITDA margin 11.6%). The net worth stands at ₹580.84 Cr (up 14.8% YoY). Total assets are valued at ₹619.51 Cr (up 14.4% YoY).
The company has about 1,153 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Windlas. As per MCA filings, the company has open charges of ₹73.3 Cr and satisfied charges of ₹183.4 Cr on record. Court records list 102 cases involving the company, including 72 filed by the company and 31 filed against it; 34 cases are pending. The company has 12 deals on record (6 secondary share transfers, 3 funding rounds, 2 market trades), with disclosed funding of ₹89.76 Cr; the latest was in September 2021. Its 8 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 5 smaller; the largest is Gufic Biosciences Limited with revenue of ₹823.43 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website windlas.com.
Company details
CIN L74899UR2001PLC033407
Registration Number 033407
Incorporation Date 19 February 2001
ROC Uttarakhand
Listing Status Listed - Listed on NSE (WINDLAS); Listed on BSE (543329)
Company Status Active
Date of Last AGM 28 July 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
CIN history
Windlas Biotech has 3 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L74899UR2001PLC033407, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L74899UR2001PLC033407 | Current |
| U74899UR2001PLC033407 | Previous |
| U74899DL2001PLC109721 | Previous |
| U74899UR2001PTC033407 | Previous |
Key People
Hitesh Windlass Managing Director Manoj Kumar Windlass Managing Director Pawan Kumar Sharma Whole-Time Director Recognitions & Rankings of Windlas Biotech
Contact details
Windlas Biotech Limited's registered office is in Dehradun, Uttarakhand. Its website is windlas.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address40/1 Mohabewala Industrial Area, Dehradun, Uttarakhand, India – 248110
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Windlas Biotech Limited, buy the company report.
Comprehensive company report
Windlas Biotech Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Windlas Biotech operates one associated brand: Windlas. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Biopharma regulatory affairs, quality control, and strategy services are provided. | windlas.com |
Business activity
The main business activity of Windlas Biotech is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Windlas Biotech Limited, buy the company report.
Financials of Windlas Biotech Limited
FY 2025-26 filings availableWindlas Biotech Limited reported revenue of ₹904.09 Cr (up 19% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹904 Cr
+19.0% YoY
EBITDA
₹105 Cr
+11.3% YoY
Profit After Tax
₹66.46 Cr
+9.0% YoY
Net Worth
₹581 Cr
+14.8% YoY
Total Assets
₹620 Cr
+14.4% YoY
Total Debt
₹35.25 Cr
+8.1% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 904 | 760 | 631 | 513 | 466 | 428 | 329 |
| Revenue growth | +19.0% | +20.4% | +23.0% | +10.1% | +9.0% | +30.0% | - |
| EBITDA | 105 | 94.10 | 78.17 | 60.23 | 52.41 | 27.26 | 34.00 |
| EBITDA margin | +11.6% | +12.4% | +12.4% | +11.7% | +11.3% | +6.4% | +10.3% |
| Profit before tax | 86.98 | 79.75 | 77.09 | 57.05 | 45.55 | 21.74 | 24.67 |
| Net profit | 66.46 | 60.98 | 58.18 | 41.99 | 38.07 | 31.31 | 16.23 |
| Net profit margin | +7.4% | +8.0% | +9.2% | +8.2% | +8.2% | +7.3% | +4.9% |
| EPS (₹) | 31.49 | 29.10 | 27.98 | 20.37 | 17.48 | 24.70 | 25.29 |
| Balance sheet | |||||||
| Total assets | 620 | 541 | 456 | 410 | 403 | 233 | 240 |
| Net worth | 581 | 506 | 450 | 402 | 395 | 199 | 210 |
| Total debt | 35.25 | 32.60 | 3.64 | 4.99 | 6.64 | 32.35 | 28.93 |
| Cash & bank | 1.81 | 15.93 | 30.95 | 25.45 | 114 | 31.11 | 18.38 |
| Net working capital | 70.64 | 82.66 | 87.73 | 128 | 229 | 109 | 47.15 |
| Cash flow | |||||||
| Cash from operations | 105 | 68.19 | 109 | 60.97 | 9.13 | 11.46 | 25.01 |
| Cash from investing | (91.79) | (74.06) | (92.07) | (14.11) | (155) | (20.20) | (14.34) |
| Cash from financing | (13.03) | 1.01 | (15.29) | (43.74) | 130 | 0.78 | (5.44) |
| Particulars | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 238 | 233 | 222 | 210 | 203 | 195 | 187 | 175 |
| Revenue growth (YoY) | +17.7% | +19.5% | +18.9% | +20.0% | +18.3% | - | - | - |
| Other income | 4.35 | 4.57 | 3.65 | 5.24 | 4.94 | 4.11 | 4.84 | 4.13 |
| EBITDA | 25.29 | 24.37 | 28.56 | 26.52 | 25.55 | 24.63 | 23.05 | 20.88 |
| EBITDA margin | +10.6% | +10.5% | +12.8% | +12.6% | +12.6% | +12.6% | +12.3% | +11.9% |
| Depreciation | 8.00 | 7.70 | 7.60 | 7.45 | 8.34 | 6.94 | 6.50 | 6.21 |
| Interest | 1.48 | 1.28 | 1.02 | 1.06 | 1.33 | 1.46 | 1.10 | 0.49 |
| Profit before tax | 20.16 | 19.96 | 23.59 | 23.25 | 20.82 | 20.34 | 20.29 | 18.31 |
| Tax | 4.18 | 4.97 | 5.79 | 5.59 | 4.55 | 4.76 | 4.63 | 4.83 |
| Net profit | 15.98 | 14.99 | 17.80 | 17.66 | 16.27 | 15.58 | 15.66 | 13.48 |
| EPS (₹) | 7.49 | 7.05 | 8.40 | 8.34 | 7.69 | 7.38 | 7.43 | 6.47 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 904 | 760 | 631 | 513 | 466 | 428 | 329 |
| Revenue growth | +19.0% | +20.4% | +23.0% | +10.1% | +9.0% | +30.0% | - |
| EBITDA | 105 | 94.11 | 78.10 | 60.25 | 52.88 | 22.34 | 40.67 |
| EBITDA margin | +11.6% | +12.4% | +12.4% | +11.7% | +11.4% | +5.2% | +12.4% |
| Profit before tax | 86.94 | 79.39 | 77.03 | 57.07 | 46.02 | 11.17 | 30.57 |
| Net profit | 66.44 | 60.64 | 58.15 | 42.01 | 38.54 | 19.49 | 22.46 |
| Net profit margin | +7.4% | +8.0% | +9.2% | +8.2% | +8.3% | +4.6% | +6.8% |
| EPS (₹) | 31.48 | 28.94 | 27.96 | 20.38 | 17.69 | 7.81 | 35.03 |
| Balance sheet | |||||||
| Total assets | 620 | 541 | 456 | 410 | 404 | 233 | 245 |
| Net worth | 581 | 506 | 450 | 403 | 395 | 199 | 216 |
| Total debt | 35.25 | 32.60 | 3.64 | 4.99 | 6.64 | 32.35 | 27.43 |
| Cash & bank | 1.81 | 15.92 | 30.90 | 25.45 | 114 | 30.96 | 18.38 |
| Net working capital | 70.64 | 82.97 | 88.08 | 128 | 229 | 109 | 47.67 |
| Cash flow | |||||||
| Cash from operations | 105 | 68.23 | 109 | 60.98 | 9.00 | 11.45 | 20.87 |
| Cash from investing | (91.79) | (74.06) | (92.07) | (14.11) | (154) | (20.19) | (9.16) |
| Cash from financing | (13.03) | 1.01 | (15.29) | (43.74) | 130 | 0.78 | (6.48) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 248 | 238 | 233 | 222 | 210 | 203 | 195 | 187 |
| Revenue growth (YoY) | +18.1% | +17.7% | +19.5% | +18.9% | +20.0% | - | - | - |
| Other income | 5.11 | 4.40 | 4.52 | 3.65 | 5.24 | 4.94 | 3.73 | 4.84 |
| Total expenses | 221 | 213 | 209 | 194 | 184 | 177 | 170 | 164 |
| EBITDA | 26.68 | 25.24 | 24.37 | 28.56 | 26.52 | 25.55 | 24.64 | 23.05 |
| EBITDA margin | +10.8% | +10.6% | +10.5% | +12.8% | +12.6% | +12.6% | +12.6% | +12.3% |
| Depreciation | 7.21 | 8.00 | 7.70 | 7.60 | 7.45 | 8.34 | 6.94 | 6.50 |
| Interest | 1.65 | 1.48 | 1.28 | 1.02 | 1.06 | 1.33 | 1.46 | 1.10 |
| Profit before tax | 22.93 | 20.16 | 19.91 | 23.59 | 23.25 | 20.82 | 19.97 | 20.29 |
| Tax | 5.28 | 4.15 | 4.97 | 5.79 | 5.59 | 4.55 | 4.74 | 4.63 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 27 Oct 2026
| Particulars | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 238 | 233 | 222 | 210 | 203 | 195 | 187 | 175 |
| Revenue growth (YoY) | +17.7% | +19.5% | +18.9% | +20.0% | +18.3% | - | - | - |
| Other income | 4.35 | 4.57 | 3.65 | 5.24 | 4.94 | 4.11 | 4.84 | 4.13 |
| EBITDA | 25.29 | 24.37 | 28.56 | 26.52 | 25.55 | 24.63 | 23.05 | 20.88 |
| EBITDA margin | +10.6% | +10.5% | +12.8% | +12.6% | +12.6% | +12.6% | +12.3% | +11.9% |
| Depreciation | 8.00 | 7.70 | 7.60 | 7.45 | 8.34 | 6.94 | 6.50 | 6.21 |
| Interest | 1.48 | 1.28 | 1.02 | 1.06 | 1.33 | 1.46 | 1.10 | 0.49 |
| Profit before tax | 20.16 | 19.96 | 23.59 | 23.25 | 20.82 | 20.34 | 20.29 | 18.31 |
| Tax | 4.18 | 4.97 | 5.79 | 5.59 | 4.55 | 4.76 | 4.63 | 4.83 |
| Net profit | 15.98 | 14.99 | 17.80 | 17.66 | 16.27 | 15.58 | 15.66 | 13.48 |
| EPS (₹) | 7.49 | 7.05 | 8.40 | 8.34 | 7.69 | 7.38 | 7.43 | 6.47 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 904 | 760 | 631 | 513 | 466 | 428 | 329 |
| Revenue growth | +19.0% | +20.4% | +23.0% | +10.1% | +9.0% | +30.0% | - |
| Other income | 17.80 | 18.02 | 13.47 | 9.97 | 6.71 | 8.74 | 2.49 |
| Total expenses | 799 | 666 | 553 | 453 | 414 | 400 | 295 |
| Employee cost | 152 | 123 | 87.46 | 70.32 | 63.41 | 58.32 | 43.57 |
| EBITDA | 105 | 94.10 | 78.17 | 60.23 | 52.41 | 27.26 | 34.00 |
| EBITDA margin | +11.6% | +12.4% | +12.4% | +11.7% | +11.3% | +6.4% | +10.3% |
| Depreciation | 30.74 | 27.99 | 13.44 | 12.36 | 12.15 | 12.97 | 9.29 |
| Interest | 4.83 | 4.38 | 1.11 | 0.79 | 1.42 | 1.29 | 2.53 |
| Profit before tax | 86.98 | 79.75 | 77.09 | 57.05 | 45.55 | 21.74 | 24.67 |
| Tax | 20.52 | 18.76 | 18.91 | 14.41 | 7.47 | 6.17 | 8.45 |
| Net profit | 66.46 | 60.98 | 58.18 | 41.99 | 38.07 | 31.31 | 16.23 |
| Net profit margin | +7.4% | +8.0% | +9.2% | +8.2% | +8.2% | +7.3% | +4.9% |
| EPS (₹) | 31.49 | 29.10 | 27.98 | 20.37 | 17.48 | 24.70 | 25.29 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 10.55 | 10.48 | 10.40 | 10.46 | 10.90 | 6.41 | 6.41 |
| Reserves & surplus | 570 | 495 | 440 | 392 | 384 | 193 | 203 |
| Shareholders' funds (net worth) | 581 | 506 | 450 | 402 | 395 | 199 | 210 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 29.88 | 27.12 | 0.11 | 0.44 | 5.76 | 30.24 | 27.43 |
| Unsecured loans | 5.37 | 5.48 | 3.53 | 4.55 | 0.88 | 2.11 | 1.50 |
| Total debt | 35.25 | 32.60 | 3.64 | 4.99 | 6.64 | 32.35 | 28.93 |
| Total liabilities | 620 | 541 | 456 | 410 | 403 | 233 | 240 |
| Assets | |||||||
| Gross block | 367 | 347 | 275 | 194 | 164 | 157 | 79.35 |
| Net block | 213 | 223 | 179 | 109 | 91.18 | 95.94 | 70.26 |
| Capital work in progress | 59.59 | 5.32 | 5.71 | 14.78 | 8.01 | 0.04 | 0.00 |
| Investments | 268 | 223 | 173 | 107 | 64.82 | 23.14 | 116 |
| Inventories | 61.82 | 81.38 | 62.19 | 74.74 | 58.71 | 41.46 | 49.32 |
| Sundry debtors | 227 | 167 | 136 | 117 | 111 | 79.41 | 63.94 |
| Cash & bank balances | 1.81 | 15.93 | 30.95 | 25.45 | 114 | 31.11 | 18.38 |
| Loans & advances | 67.44 | 37.59 | 28.44 | 29.97 | 33.52 | 19.19 | 14.11 |
| Total current assets | 358 | 302 | 258 | 247 | 317 | 171 | 146 |
| Total current liabilities | 288 | 219 | 170 | 119 | 87.79 | 62.41 | 98.60 |
| Net working capital | 70.64 | 82.66 | 87.73 | 128 | 229 | 109 | 47.15 |
| Total assets | 620 | 541 | 456 | 410 | 403 | 233 | 240 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.42 | 5.29 | 3.69 | 0.57 | 15.93 | 23.90 | 12.86 |
| Net cash from operating activities | 105 | 68.19 | 109 | 60.97 | 9.13 | 11.46 | 25.01 |
| Net cash from investing activities | (91.79) | (74.06) | (92.07) | (14.11) | (155) | (20.20) | (14.34) |
| Net cash from financing activities | (13.03) | 1.01 | (15.29) | (43.74) | 130 | 0.78 | (5.44) |
| Net change in cash | 0.11 | (4.86) | 1.60 | 3.12 | (15.36) | (7.97) | 5.22 |
| Closing cash | 1.81 | 15.93 | 30.95 | 25.45 | 114 | 31.11 | 18.38 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +19.0% | +20.4% | +23.0% | +10.1% | +9.0% | +30.0% | - |
| EBITDA growth | +11.3% | +20.4% | +29.8% | +14.9% | +92.3% | -19.8% | - |
| PBT growth | +9.1% | +3.5% | +35.1% | +25.3% | +109.5% | -11.9% | -67.6% |
| Net income growth | +9.0% | +4.8% | +38.6% | +10.3% | +21.6% | +92.9% | - |
| Revenue CAGR (3Y) | +20.8% | +17.7% | +13.9% | +16.0% | +14.9% | +6.7% | - |
| EBITDA CAGR (3Y) | +20.3% | +21.5% | +42.1% | +21.0% | +11.6% | -11.5% | - |
| Profitability & leverage | |||||||
| Net income margin | +7.4% | +8.0% | +9.2% | +8.3% | +8.2% | +3.6% | +4.9% |
| Return on capital employed | +15.8% | +16.9% | +18.1% | +14.2% | +14.8% | +18.9% | +11.7% |
| Return on net worth | +12.2% | +12.8% | +13.7% | +10.7% | +12.8% | +15.2% | +8.0% |
| Debt / equity | 0.06 | 0.04 | 0.01 | 0.01 | 0.07 | 0.15 | 0.15 |
| Long-term debt / equity | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 | 0.02 |
| Interest cover | 6.53 | 6.63 | 1.71 | 1.65 | 3.53 | 9.03 | 10.24 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 2.54 | 2.45 | 2.69 | 2.87 | 2.90 | 3.62 | 4.01 |
| Inventory turnover | 12.63 | 10.59 | 9.22 | 7.69 | 9.30 | 9.42 | 9.62 |
| Debtors turnover | 4.59 | 5.01 | 4.99 | 4.51 | 4.90 | 5.97 | 5.23 |
| EPS (₹) | 31.49 | 29.10 | 27.98 | 20.37 | 17.48 | 24.70 | 25.29 |
| Dividend per share (₹) | 6.30 | 5.80 | 5.50 | 4.00 | 3.50 | 0.00 | 0.00 |
| Book value per share (₹) | 275.20 | 241.30 | 216.34 | 192.24 | 181.14 | 310.59 | 327.03 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 248 | 238 | 233 | 222 | 210 | 203 | 195 | 187 |
| Revenue growth (YoY) | +18.1% | +17.7% | +19.5% | +18.9% | +20.0% | - | - | - |
| Other income | 5.11 | 4.40 | 4.52 | 3.65 | 5.24 | 4.94 | 3.73 | 4.84 |
| Total expenses | 221 | 213 | 209 | 194 | 184 | 177 | 170 | 164 |
| EBITDA | 26.68 | 25.24 | 24.37 | 28.56 | 26.52 | 25.55 | 24.64 | 23.05 |
| EBITDA margin | +10.8% | +10.6% | +10.5% | +12.8% | +12.6% | +12.6% | +12.6% | +12.3% |
| Depreciation | 7.21 | 8.00 | 7.70 | 7.60 | 7.45 | 8.34 | 6.94 | 6.50 |
| Interest | 1.65 | 1.48 | 1.28 | 1.02 | 1.06 | 1.33 | 1.46 | 1.10 |
| Profit before tax | 22.93 | 20.16 | 19.91 | 23.59 | 23.25 | 20.82 | 19.97 | 20.29 |
| Tax | 5.28 | 4.15 | 4.97 | 5.79 | 5.59 | 4.55 | 4.74 | 4.63 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 904 | 760 | 631 | 513 | 466 | 428 | 329 |
| Revenue growth | +19.0% | +20.4% | +23.0% | +10.1% | +9.0% | +30.0% | - |
| Other income | 17.80 | 17.65 | 13.47 | 9.97 | 6.71 | 3.09 | 0.96 |
| Total expenses | 799 | 666 | 553 | 453 | 413 | 405 | 288 |
| Employee cost | 152 | 123 | 87.46 | 70.32 | 63.41 | 58.32 | 43.88 |
| EBITDA | 105 | 94.11 | 78.10 | 60.25 | 52.88 | 22.34 | 40.67 |
| EBITDA margin | +11.6% | +12.4% | +12.4% | +11.7% | +11.4% | +5.2% | +12.4% |
| Depreciation | 30.74 | 27.99 | 13.44 | 12.36 | 12.15 | 12.97 | 8.69 |
| Interest | 4.83 | 4.38 | 1.10 | 0.79 | 1.42 | 1.29 | 2.37 |
| Profit before tax | 86.94 | 79.39 | 77.03 | 57.07 | 46.02 | 11.17 | 30.57 |
| Tax | 20.50 | 18.74 | 18.88 | 14.41 | 7.47 | 6.17 | 8.11 |
| Net profit | 66.44 | 60.64 | 58.15 | 42.01 | 38.54 | 19.49 | 22.46 |
| Net profit margin | +7.4% | +8.0% | +9.2% | +8.2% | +8.3% | +4.6% | +6.8% |
| EPS (₹) | 31.48 | 28.94 | 27.96 | 20.38 | 17.69 | 7.81 | 35.03 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 10.55 | 10.48 | 10.40 | 10.46 | 10.90 | 6.41 | 6.41 |
| Reserves & surplus | 570 | 495 | 440 | 392 | 384 | 193 | 210 |
| Shareholders' funds (net worth) | 581 | 506 | 450 | 403 | 395 | 199 | 216 |
| Secured loans | 29.88 | 27.12 | 0.11 | 0.44 | 6.12 | 30.24 | 22.16 |
| Unsecured loans | 5.37 | 5.48 | 3.53 | 4.55 | 0.52 | 2.11 | 5.27 |
| Total debt | 35.25 | 32.60 | 3.64 | 4.99 | 6.64 | 32.35 | 27.43 |
| Total liabilities | 620 | 541 | 456 | 410 | 404 | 233 | 245 |
| Assets | |||||||
| Gross block | 367 | 346 | 274 | 193 | 164 | 157 | 141 |
| Net block | 213 | 223 | 179 | 109 | 91.18 | 95.94 | 68.43 |
| Capital work in progress | 59.59 | 5.32 | 5.71 | 14.78 | 8.01 | 0.04 | 0.00 |
| Investments | 268 | 223 | 173 | 107 | 64.86 | 23.18 | 121 |
| Inventories | 61.82 | 81.38 | 62.19 | 74.74 | 58.71 | 41.46 | 49.32 |
| Sundry debtors | 227 | 167 | 136 | 117 | 111 | 79.41 | 64.56 |
| Cash & bank balances | 1.81 | 15.92 | 30.90 | 25.45 | 114 | 30.96 | 18.38 |
| Loans & advances | 67.44 | 37.89 | 28.44 | 29.97 | 33.52 | 19.18 | 14.11 |
| Total current assets | 358 | 302 | 258 | 247 | 317 | 171 | 146 |
| Total current liabilities | 288 | 219 | 170 | 119 | 87.46 | 62.42 | 98.70 |
| Net working capital | 70.64 | 82.97 | 88.08 | 128 | 229 | 109 | 47.67 |
| Total assets | 620 | 541 | 456 | 410 | 404 | 233 | 245 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.42 | 5.24 | 3.69 | 0.55 | 15.78 | 23.74 | 12.86 |
| Net cash from operating activities | 105 | 68.23 | 109 | 60.98 | 9.00 | 11.45 | 20.87 |
| Net cash from investing activities | (91.79) | (74.06) | (92.07) | (14.11) | (154) | (20.19) | (9.16) |
| Net cash from financing activities | (13.03) | 1.01 | (15.29) | (43.74) | 130 | 0.78 | (6.48) |
| Net change in cash | 0.11 | (4.82) | 1.56 | 3.13 | (15.22) | (7.97) | 5.22 |
| Closing cash | 1.81 | 15.92 | 30.90 | 25.45 | 114 | 30.96 | 18.38 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +19.0% | +20.4% | +23.0% | +10.1% | +9.0% | +30.0% | - |
| EBITDA growth | +11.3% | +20.5% | +29.6% | +13.9% | +136.7% | -45.1% | - |
| PBT growth | +9.5% | +3.1% | +35.0% | +24.0% | +312.0% | -63.5% | -12.3% |
| Net income growth | +9.6% | +4.3% | +38.4% | +9.0% | +97.7% | -13.2% | - |
| Revenue CAGR (3Y) | +20.8% | +17.7% | +13.9% | +16.0% | +17.4% | +10.1% | +1.4% |
| EBITDA CAGR (3Y) | +20.2% | +21.2% | +51.8% | +14.0% | +6.0% | -16.5% | +17.9% |
| Profitability & leverage | |||||||
| Net income margin | +7.4% | +8.0% | +9.2% | +8.3% | +8.3% | +1.2% | +6.8% |
| Return on capital employed | +15.8% | +16.8% | +18.0% | +14.2% | +14.9% | +18.8% | +14.0% |
| Return on net worth | +12.2% | +12.7% | +13.6% | +10.7% | +13.0% | +9.4% | +10.9% |
| Debt / equity | 0.06 | 0.04 | 0.01 | 0.01 | 0.07 | 0.14 | 0.14 |
| Long-term debt / equity | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 | 0.02 |
| Interest cover | 6.53 | 6.62 | 1.70 | 1.65 | 3.49 | 13.77 | 7.41 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 2.54 | 2.45 | 2.70 | 2.87 | 2.90 | 2.87 | 2.47 |
| Inventory turnover | 12.63 | 10.59 | 9.22 | 7.69 | 9.30 | 9.42 | 9.62 |
| Debtors turnover | 4.59 | 5.01 | 4.99 | 4.51 | 4.90 | 5.94 | 5.19 |
| EPS (₹) | 31.48 | 28.94 | 27.96 | 20.38 | 17.69 | 7.81 | 35.03 |
| Dividend per share (₹) | 6.30 | 5.80 | 5.50 | 4.00 | 3.50 | 0.00 | 0.00 |
| Book value per share (₹) | 275.20 | 241.31 | 216.51 | 192.42 | 181.30 | 310.39 | 337.66 |
To see the full year-wise statements and ratios of Windlas Biotech Limited, buy the company report.
Board of directors of Windlas Biotech Limited
Windlas Biotech has 8 current directors and 12 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Pawan Kumar Sharma | Whole-Time Director | 11 Jun 2019 | 7 Years 4 Months | Current |
| Prachi Jain Windlass Also directs: Michael & Susan Dell Foundation India LLP | Director | 03 May 2021 | 5 Years 5 Months | Current |
| Vivek Dhariwal | Director | 06 May 2021 | 5 Years 5 Months | Current |
| Gaurav Gulati Also directs: Aroa Innovation Partners LLP, Redsprig Innovation Partners LLP, Dagrowave Agscience Private Limited and 5 more | Director | 06 May 2021 | 5 Years 5 Months | Current |
| Hitesh Windlass | Managing Director | 21 Jan 2008 | 18 Years 9 Months | Current |
| Manoj Kumar Windlass Also directs: Windlas Exports Private Limited | Managing Director | 01 Apr 2006 | 20 Years 6 Months | Current |
Showing 6 of 8 current directors. View all directors
Peer comparison
Windlas Biotech Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Windlas Biotech Limitedthis company | ₹904.09 Cr (FY 2026) | ₹66.46 Cr | 7.4% | 19.0% | 1,153 | Dehradun, Uttarakhand, India |
| Gufic Biosciences Limited | ₹823.43 Cr (FY 2025) | 2.0% | Mumbai, Maharashtra, India | |||
| Synokem Pharmaceuticals Limited | ₹791.15 Cr (FY 2025) | 0.0% | New Delhi, Delhi, India | |||
| Prime Pharmaceuticals Private Limited | ₹783.06 Cr (FY 2025) | 131.0% | Mumbai, Maharashtra, India | |||
| Fourrts (India) Laboratories Private Limited | ₹760.55 Cr (FY 2024) | 7.0% | Chennai, Tamil Nadu, India | |||
| Pritam International Private Limited | ₹758.46 Cr (FY 2025) | 15.0% | Kolkata, West Bengal, India | |||
| Indchemie Health Specialities Private Limited | ₹734.44 Cr (FY 2025) | 5.0% | Mumbai, Maharashtra, India | |||
| Sanofi-Synthelabo (India) Private Limited | ₹729.49 Cr (FY 2020) | 16.0% | Mumbai, Maharashtra, India | |||
| Apotex Research Private Limited | ₹727.34 Cr (FY 2025) | 22.0% | Jigani Hobli, Karnataka, India |
To see the full peer comparison of Windlas Biotech Limited, buy the company report.
Auditor
Windlas Biotech Limited is audited by SS KOTHARI METHA & COMPANY LLP for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| SS KOTHARI METHA & COMPANY LLP | FY 2025 | 000756N |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 63.30%, foreign institutional investors hold 2.00%, domestic institutional investors hold 9.90% and retail and other public shareholders hold 24.80%.
Sep 2026
QUARTER
63.30% Promoters
9.90% DII (Domestic Institutional)
2.00% FII (Foreign Institutional)
24.80% Retail & Others
Promoter holding - history
Now 63.30% · Sep 2026High 63.30% · Sep 2026Low 61.90% · Jun 2026
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 63.30% | 61.90% | 62.00% | 62.00% |
| Public | 36.70% | 38.10% | 38.00% | 38.00% |
Charges & borrowings
Open charges
₹73.3 Cr
Satisfied charges
₹183.4 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 27 May 2022 | 100575416 | The Hongkong and Shanghai Banking Corporation Limited | ₹40 Cr | Open | |
| 04 Feb 2015 | 10547318 | Others | ₹10 Cr | Open | |
| 28 Apr 2010 | 10223457 | Hdfc Bank Limited | ₹23.3 Cr | Open | |
| 16 Apr 2021 | 100443787 | Others | ₹20 Cr | Satisfied | |
| 16 Mar 2021 | 100446265 | Others | ₹20 Cr | Satisfied |
To see the full charge records of Windlas Biotech Limited, buy the company report.
Total charge records: 29 View all charges
Deals & funding
Windlas Biotech Limited has 12 deals on record (6 secondary share transfers, 3 funding rounds, 2 market trades), with disclosed funding of ₹89.76 Cr; the latest was in September 2021.
Total deals
12
Secondary share transfers
6
Funding rounds
3
Market trades
2
IPO
1
Disclosed funding
₹89.76 Cr
Deals on record (5 of 12)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2021 | Market trade | ₹4.31 Cr | Seller: Kuber India Fund |
| Aug 2021 | Market trade | ₹10.05 Cr | Buyer: Alphagrep Securities Private Limited Seller: Icici Ltd Trading A/C, Alphagrep Securities Private Limited |
| Aug 2021 | IPO | ₹401.54 Cr | Investors: IPO Shareholders - Windlas Biotech Limited, Icici Prudential Pharma Healthcare Diaganostics P.H.D. Fund, Macquarie Fund Solutions - Macquarie Asia New Stars Fund Seller: Tano Capital, an individual |
| Mar 2021 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Dec 2018 | Funding round | ₹4.82 Cr | Investors: an individual |
To see the full deal history of Windlas Biotech Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Windlas Biotech Limited has 102 court cases on record: 72 filed by Windlas Biotech, 31 filed against it. 34 cases are pending and 68 are disposed.
Total cases
102
Filed by the company
72
Filed against the company
31
Pending
34
Disposed
68
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 59 | 15 | 24 |
| High courts | 39 | 13 | 10 |
| Supreme Court | 4 | 3 | 0 |
Cases on record (5 of 102)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Dehradun, Uttarakhand | Criminal case | Filed by the company against M/S Esteve Pharma Ltd and Others | Pending |
| High Court | Court case (COMIP) | Filed against the company by Glenmark Pharmaceuticals Ltd | Pending |
| High Court, MAHARASHTRA | Court case (LPETN) | Filed against the company by Wockhardt Limited | Pending |
| High Court, TAMIL NADU | Appeal | Filed against the company by Sun Pharmaceutical Medicare Limited | Pending |
| District court, Dehradun, Uttarakhand | Interim or miscellaneous application | Filed by the company against Suncure Lifescience Pvt Ltd and Others | Disposed |
To see the full case history of Windlas Biotech Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Windlas Biotech Limited was last rated by Icra on 24 Sep 2021.
| Rating agency | Rated on | Rating |
|---|---|---|
| Icra | 24 Sep 2021 |
To see the full credit ratings and regulatory alerts of Windlas Biotech Limited, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Windlas Biotech Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Windlas Biotech Limited has a workforce of 1,153 employees on its EPFO records as of Feb 18, 2026, across 1 active EPFO establishment.
Employee count
1,153
Active EPFO establishments
1
Employee growth
8.57%
GST
Windlas Biotech has 12 GST registrations: 7 active and 5 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
12
Active
7
Cancelled / inactive
5
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 05AAACW3417C1ZV | Uttarakhand | Active | 01 Jul 2017 |
| 09AAACW3417C1ZN | Uttar Pradesh | Active | 01 Jul 2017 |
| 10AAACW3417C1Z4 | Bihar | Active | 01 Jul 2017 |
| 23AAACW3417C1ZX | Madhya Pradesh | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Windlas Biotech Limited, buy the company report.
Recent activity
Windlas Biotech Limited has 25 board changes on record since 2001: 17 appointments and 8 cessations. The latest: Tarashree Singhal was appointed as Additional Director on 05 May 2026.
Appointed
Tarashree Singhal was appointed as Additional Director.
Filing
Windlas Biotech Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Uttarakhand.
AGM
Windlas Biotech Limited last Annual general meeting of members was held on 28 Jul 2025 as per latest MCA records.
Charges
A charge registered on 13 Jul 2020 via Charge ID 100360093 with Sidbi was fully satisfied on 20 Mar 2025.
Charges
A charge with The Hongkong And Shanghai Banking Corporation Limited of Rs. 40.00 Cr registered on 27 May 2022 with Charge ID 100575416 was modified on 17 Mar 2025.
Charges
A charge with Hdfc Bank Limited of Rs. 23.30 Cr registered on 28 Apr 2010 with Charge ID 10223457 was modified on 08 Jan 2025.
Charges
A charge with Others of Rs. 10.00 Cr registered on 04 Feb 2015 with Charge ID 10547318 was modified on 30 Apr 2024.
Charges
A charge registered on 29 Mar 2019 via Charge ID 100249120 with Sidbi was fully satisfied on 14 Feb 2024.
Charges
A charge registered on 29 Dec 2010 via Charge ID 10309166 with Hdfc Bank Limited was fully satisfied on 13 Feb 2024.
Charges
A charge registered on 28 May 2001 via Charge ID 90048511 with State Bank Of India was fully satisfied on 24 Apr 2023.
Charges
A charge registered on 16 Mar 2021 via Charge ID 100446265 with Others was fully satisfied on 16 Aug 2022.
Charges
A charge with The Hongkong And Shanghai Banking Corporation Limited amounted to Rs. 40.00 Cr with Charge ID 100575416 was registered on 27 May 2022.
83 earlier events are in the company report.
News
Frequently asked questions
Windlas Biotech is an active public limited company based in Dehradun, Uttarakhand, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 19 February 2001 (25+ years old) and is registered under CIN L74899UR2001PLC033407. Listed on BSE: 543329 and NSE: WINDLAS.
Windlas Biotech reported revenue of ₹904.09 Cr for FY 2025-26 (up 19% YoY) based on consolidated financials.
Windlas Biotech has 8 current directors:
- Hitesh Windlass - Managing Director
- Manoj Kumar Windlass - Managing Director
- Pawan Kumar Sharma - Whole-Time Director
- Ashok Kumar Windlass - Whole-Time Director
- Prachi Jain Windlass - Director
- Vivek Dhariwal - Director
- Gaurav Gulati - Director
- Tarashree Singhal - Additional Director
The latest financial statements of Windlas Biotech on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 28 July 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Windlas Biotech is 05AAACW3417C1ZV, registered in Uttarakhand. The company has 12 GST registrations in all, of which 7 are active and 5 are cancelled or inactive. Other active GSTINs include 09AAACW3417C1ZN (Uttar Pradesh), 10AAACW3417C1Z4 (Bihar), 23AAACW3417C1ZX (Madhya Pradesh).
The CIN (Corporate Identification Number) of Windlas Biotech is L74899UR2001PLC033407. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Windlas Biotech is a listed company as per MCA records. Its shares are listed on both BSE (code: 543329) and NSE (symbol: WINDLAS).
Windlas Biotech has 102 court cases on record: 72 filed by the company and 31 filed against it. 34 are pending. Most are in the district courts.
Windlas Biotech was incorporated on 19 February 2001, making it 25+ years old. It is registered with the Registrar of Companies, Uttarakhand.
Windlas Biotech has 12 deals on record (6 secondary share transfers, 3 funding rounds, 2 market trades), with disclosed funding of ₹89.76 Cr; the latest was in September 2021.
The peers of Windlas Biotech by revenue are Gufic Biosciences Limited, Synokem Pharmaceuticals Limited, Prime Pharmaceuticals Private Limited, Fourrts (India) Laboratories Private Limited, Pritam International Private Limited and 3 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).